Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin, Gemcitabine and Bevacizumab in Recurrent Mullerian Carcinoma
NCT00418093Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2006
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Partial Response Rate at 18 weeks. Started Sep 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00418093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418093.